Search results for "hormone replacement therapy"

showing 10 items of 72 documents

Association of childhood cancer with factors related to pregnancy and birth

1999

It has been hypothesized that risk factors of childhood cancers may already operate during the prenatal and neonatal period. Results of previous epidemiological studies have been inconsistent.During 1992-1997 a large case-control study on childhood cancers and a variety of potential risk factors was conducted in Germany. Cases were ascertained by the German Childhood Cancer Registry. Each case was matched to a population-based control of the same age and gender, sampled from the district where the case lived at the date of diagnosis. For the analyses, 2358 cases and 2588 controls were available.Risk of childhood acute leukaemia increased with maternal ageor =20 years at time of delivery (od…

AdultMalePediatricsmedicine.medical_specialtyAdolescentHormone Replacement TherapyEpidemiologyBirth weightPopulationBone NeoplasmsSoft Tissue NeoplasmsPrenatal careCentral Nervous System NeoplasmsPregnancyRisk FactorsGermanyOdds RatiomedicineBirth WeightHumansRegistriesRisk factorChildeducationRetrospective Studieseducation.field_of_studyChildhood Cancer RegistryPregnancybusiness.industryLymphoma Non-HodgkinSmokingInfant NewbornCase-control studyInfantGeneral MedicineOdds ratioPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseParityMaternal ExposureChild PreschoolPrenatal Exposure Delayed EffectsFemalebusinessMaternal AgeInternational Journal of Epidemiology
researchProduct

Gender-, age- and time-dependent dosing of growth hormone in adults - real-world data from a decade of clinical practice in Germany.

2017

We evaluated treatment patterns and gender-dependent dosing of growth hormone (GH) substitution in adults with GH deficiency (AGHD). Data on GH dose were collected (2003-2013) from 509 GH-treated patients (mean age: 48.9 years; 47% female) enroled in the observational German NordiWin study (NCT01543880). The impact of gender, age, treatment duration and calendar year on GH treatment patterns was evaluated by multiple regression analysis. Mean (SD) baseline GH dose (mg/day) was similar between females (0.25 [0.19] and males (0.24 [0.15]), but increased with treatment duration (at year 10, 0.55 [0.48] and 0.31 [0.09] in females and males, respectively), reflecting patient dose titration. GH d…

AdultMalemedicine.medical_specialtyHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPhysiology030209 endocrinology & metabolismGrowth hormoneGrowth hormone deficiency03 medical and health sciencesInsulin-like growth factor0302 clinical medicineEndocrinologySex FactorsInternal medicineGermanymedicineHumansDosingDwarfism PituitaryAgedDose-Response Relationship Drugbusiness.industryHuman Growth HormoneAge FactorsObstetrics and GynecologyMiddle Agedmedicine.diseaseClinical PracticeEndocrinologyTreatment OutcomeTransgender hormone therapy030220 oncology & carcinogenesisGh treatmentFemalebusinessReal world dataGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
researchProduct

Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-t…

2007

Objective: Patients with growth hormone deficiency (GHD) have increased cardiovascular risk and may show elevated triglyceride and reduced high density lipoprotein (HDL) cholesterol concentrations, two lipid abnormalities usually accompanied by increased small dense LDL in the ‘atherogenic lipoprotein phenotype’ (ALP). In the present study, we directly investigated (1) whether hypopituitary patients with GHD have increased small dense LDL; (2) whether growth hormone replacement therapy (GHRT) beneficially impact on such particles; (3) the prevalence of ALP in GHD and GHRT patients. Design and methods: In 14 hypopituitary patients with GHD (44 ± 13 years, body mass index (BMI) 27 ± 3) before…

AdultMalemedicine.medical_specialtyTime FactorsArteriosclerosisHormone Replacement TherapyEndocrinology Diabetes and MetabolismBiologyHypopituitarismGrowth hormone deficiencychemistry.chemical_compoundEndocrinologyInternal medicinemedicineHumansIn patientInsulin-Like Growth Factor ITriglyceridesTriglycerideHuman Growth HormoneCholesterolVascular diseaseCholesterol HDLGeneral MedicineMiddle AgedAtherogenic lipoprotein phenotypemedicine.diseaseLipoproteins LDLCholesterolTreatment OutcomeEndocrinologyAtheromachemistryLow-density lipoproteinElectrophoresis Polyacrylamide GelFemalelipids (amino acids peptides and proteins)European Journal of Endocrinology
researchProduct

Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy.

2009

Background Hereditary angioedema caused by mutations in the factor XII gene is a recently described disease entity that occurs mainly in women. It differs from hereditary angioedema caused by C1 inhibitor deficiency. Objective To assess the clinical symptoms, factors triggering acute attacks, and treatments of this disease. Methods Thirty-five female patients with hereditary angioedema and the factor XII mutations p.Thr309Lys and p.Thr309Arg who came from 13 unrelated families were studied. The observation period was 8.4 years on average (range, 2-26 years). Results Patients had on average 12.7 ± 7.9 angioedema attacks per year. Recurrent facial swellings occurred in all patients; skin swel…

Adultmedicine.medical_specialtyAbdominal painAdolescentmedicine.medical_treatmentImmunologyMutation MissenseSeverity of Illness IndexC1-inhibitorYoung AdultRisk FactorsSurveys and QuestionnairesImmunology and AllergyMedicineHumansHereditary Angioedema Type IIIAge of OnsetChildProgesteroneDanazolPregnancyAngioedemabiologybusiness.industryDanazolAngioedemas HereditaryHormone replacement therapy (menopause)Middle Agedmedicine.diseaseDermatologySurgeryPedigreeTranexamic AcidHereditary angioedemaFactor XIIbiology.proteinFemalemedicine.symptombusinessmedicine.drugThe Journal of allergy and clinical immunology
researchProduct

Hypogonadism and Hormone Replacement Therapy on Bone Mass of Adult Women with Thalassemia Major

2002

We studied bone mass and metabolism in 30 adult women (age 28.5 +/- 1.3) with thalassemia major (TM) and evaluated whether prolonged hormone replacement therapy (HRT) was able to optimize bone accrual. TM patients had reduced bone mass, increased bone turnover and lower serum gonadotropin and estradiol levels compared with 10 normal women of similar age. A significant correlation was found between bone mass and sex hormone levels. Six TM patients with normal ovarian function had normal bone turnover markers and modestly low bone mass (lumbar spine -1.29 +/- 0.31; femoral neck -0.60+/-0.21; Z-score). The other 24 TM women were hypogonadic and had significantly lower bone mass for age (lumbar…

Adultmedicine.medical_specialtyHormone Replacement TherapyEndocrinology Diabetes and MetabolismThalassemiaOsteoporosisBone remodelingAdult womenEndocrinologySex hormone-binding globulinBone DensityInternal medicinemedicineHumansOrthopedics and Sports MedicineFemoral neckEstradiolbiologybusiness.industryHypogonadismbeta-ThalassemiaOsteoporosiLuteinizing Hormonemedicine.diseaseThalassaemiaEndocrinologymedicine.anatomical_structureTransgender hormone therapyOrthopedic surgerybiology.proteinFemaleFollicle Stimulating HormonebusinessCalcified Tissue International
researchProduct

Analysis of serum and endometrial progesterone in determining endometrial receptivity.

2021

Abstract STUDY QUESTION Is there a relationship between serum and endometrial progesterone (P4) levels, including P4 and metabolites (oestrone, oestradiol and 17α-hydroxyprogesterone), and endometrial receptivity? SUMMARY ANSWER Serum P4 levels were not correlated with endometrial P4, nor associated with endometrial receptivity as determined by the ERA® test; however, endometrial P4 and 17α-hydroxyprogesterone levels were positively correlated and related to endometrial receptivity by ERA. WHAT IS KNOWN ALREADY Acquisition of endometrial receptivity is governed by P4, which induces secretory transformation. A close relationship between serum P4 and pregnancy outcome is reported for hormone …

Adultmedicine.medical_specialtyPregnancy Ratemedicine.medical_treatmentPopulationUterusLuteal phaseEndometriumEndometriumPregnancyMedicine17a-hydroxyprogesterone ERA test P4 endometrial receptivity progesterone steroid hormones metabolitesHumansEmbryo ImplantationProspective StudieseducationProspective cohort studyProgesteroneGynecologyeducation.field_of_studyPregnancymedicine.diagnostic_testbusiness.industryRehabilitationObstetrics and GynecologyHormone replacement therapy (menopause)medicine.diseaseEmbryo Transfermedicine.anatomical_structureReproductive MedicineFemalebusinesshormones hormone substitutes and hormone antagonistsEndometrial biopsyHuman reproduction (Oxford, England)
researchProduct

Associations of Sex Hormones and Hormonal Status With Arterial Stiffness in a Female Sample From Reproductive Years to Menopause

2021

Objective: Loss of sex hormones has been suggested to underlie menopause-associated increment in cardiovascular risk. We investigated associations of sex hormones with arterial stiffness in 19–58-years-old women. We also studied associations of specific hormonal stages, including natural menstrual cycle, cycle with combined oral contraceptives (COC) and menopausal status with or without hormone therapy (HT), with arterial stiffness. Methods: This study includes repeated measurements of 65 healthy women representing reproductive (n=16 natural, n=10 COC-users) and menopause (n=5 perimenopausal, n=26 postmenopausal, n=8 HT-users) stages. Arterial stiffness outcomes were aortic pulse wave veloc…

AdultnaisetAdolescentvaihdevuodetBlood PressurekuukautisetPulse Wave Analysisreproductive hormoneshormonaaliset tekijätYoung AdultEndocrinologyVascular StiffnessHeart Ratewomen’s healthHumanspulse wave analysisArterial PressureGonadal Steroid HormonesMenstrual CycleOriginal ResearchsukupuolihormonitEstradiolhormonal contraceptionvascular stiffnessMiddle Agedhormone replacement therapyikääntyminenkuukautiskiertoFollicular Phasevascular aginghormonihoitosydän- ja verisuonitauditFemaleFollicle Stimulating HormoneMenopausemenstruation
researchProduct

Power training and postmenopausal hormone therapy affect transcriptional control of specific co-regulated gene clusters in skeletal muscle

2010

At the moment, there is no clear molecular explanation for the steeper decline in muscle performance after menopause or the mechanisms of counteractive treatments. The goal of this genome-wide study was to identify the genes and gene clusters through which power training (PT) comprising jumping activities or estrogen containing hormone replacement therapy (HRT) may affect skeletal muscle properties after menopause. We used musculus vastus lateralis samples from early stage postmenopausal (50–57 years old) women participating in a yearlong randomized double-blind placebo-controlled trial with PT and HRT interventions. Using microarray platform with over 24,000 probes, we identified 665 diffe…

AgingCandidate geneTranscription GeneticvaihdevuodetmenopaussiBioinformaticsEstrogen deprivation0302 clinical medicineGene expressionestrogenTranscriptional regulation0303 health sciencesEstrogen Replacement TherapyGeneral MedicineMiddle AgedestrogeeniPostmenopausemedicine.anatomical_structureFemalevoimaharjoitteluMenopausemedicine.symptomTranscriptome-wide studymedicine.medical_specialtyPlyometric trainingmedicine.drug_classBiologyArticletranskriptomin laajuuinen tutkimus03 medical and health sciencesplyometrinen harjoitteluInternal medicinemedicineHumansSkeletal muscle characteristicsKEGGMuscle SkeletalExerciseGene030304 developmental biologyhormonikorvaushoitoSkeletal muscleMuscle weaknessdeprivaatioPower trainingAgeingEndocrinologyluurankolihaksetHormone replacement therapyEstrogenGeriatrics and Gerontology030217 neurology & neurosurgeryAGE
researchProduct

Biological clocks and physical functioning in monozygotic female twins

2018

Background Biomarkers of biological aging – DNA methylation age (DNAm age) and leukocyte telomere length (LTL)– correlate strongly with chronological age across the life course. It is, however, unclear how these measures of cellular wear and tear are associated with muscle strength and functional capacity, which are known to decline with older age and are associated with mortality. We investigated if DNAm age and LTL were associated with body composition and physical functioning by examining 48 monozygotic twin sisters. Methods White blood cell DNAm age (predicted years) was calculated from Illumina 450 k BeadChip methylation data using an online calculator. DNAm age acceleration was define…

AgingEpigenetic clockTwin designfyysinen toimintakykybiomarkkeritWalkinglcsh:GeriatricsMethylationphysical functionAGEBiological ClocksPost-menopausalHumansMuscle Strengthpost-menopausalkaksostutkimusOLDERHERITABILITYHORMONE REPLACEMENT THERAPYMORTALITYTwins MonozygoticMiddle AgedBODY-MASS INDEXlcsh:RC952-954.6ikääntyminenTelomerestwin design3121 General medicine internal medicine and other clinical medicineTELOMERE LENGTHBody CompositionPhysical functionSKELETAL-MUSCLEFemaletelomeeritGRIP STRENGTHmethylationepigenetic clockResearch Article
researchProduct

Postural balance and health-related factors in middle-aged and older women with injurious falls and non-fallers.

2004

Background and aims: Older jailers aged over 70 years have shown impaired balance abilities, but it is unclear if impairment in balance control can be detected among jallers who are in their 50’s and 60’s. The aim oj this study was to analyze possible differences in balance control and other health-related factors between female fallers and nonfallers aged 50–68 years. Methods: Women 50–68 years of age (N=40) who had fallen outside and needed medical attention were recruited through a larger fall accident study. Non-fallers (N=97) were women representing the same age group who had not fallen during the preceding 12 months. A battery of standing force platform balance tests were administered…

Agingmedicine.medical_specialtyHormone Replacement TherapyHealth StatusMovementStatistics as TopicPoison controlBlood PressureSuicide preventionDizzinessOccupational safety and healthInterviews as TopicRisk FactorsInjury preventionmedicinePostural BalanceHumansForce platformBody Weights and MeasuresHearing LossPostural BalanceFinlandVision OcularBalance (ability)AgedImpaired Balancebusiness.industryAge FactorsMiddle AgedChronic DiseasePhysical therapyAccidental FallsFemaleGeriatrics and GerontologybusinessVisually Impaired PersonsAging clinical and experimental research
researchProduct